LONDON, April 3 /PRNewswire/ -- Developers of assays for in-vitro diagnostics need to overcome the significant challenge of proving the worth of their technologies, to ease potential end users' scepticism about the reliability of new assays. Their apprehensions can be resolved only through effective demonstrations and education about the remarkable benefits of these assays.
Companies need to train lab personnel on the use of these new tests as well as educate physicians about the ability of these assays to improve the overall cost efficiency and patient outcomes. This can be achieved through accurate and early diagnosis of life-threatening diseases by application of these assays.
There has been wider acceptance of newly developed tumour and prostrate markers, breast cancer tests and assay technologies because of their high sensitivity as well as their specificity, fast turn-around times, easy-to-use interfaces and low-cross reactivity.
"The tests need to be easily accessible to end users across the world and not merely restricted to those in developed countries," says Frost & Sullivan (http://ti.frost.com) Senior Research Analyst Sachin Thukral. "It is vital to make them available in developing countries, where there is widespread prevalence of diseases requiring these assays."
European companies have proactively developed several new technologies to expand the base of diagnosable diseases. For instance, a Norwegian biotechnology company has invented a novel diagnostic method that involves analysis of gene expression patterns in easily available clinical samples such as peripheral blood. Such technologies can be used to develop new diagnostic tests for major diseases including breast cancer and Alzheimer's.
Another London based company has collaborated with the biomaterials department at the University of Limerick to develop Selectis Bone Quality Test (BQT), a new technique for assessing osteoporosis-related fracture risk, using the advanced Raman laser system. The BQT is considered the most accurate predictor of osteoporotic fracture.
It all starts with companies identifying the need and market for such sophisticated assays, and then finding a suitable technology platform that can provide real-time, dependable and accurate laboratory-grade results. The next step, however, is to solve automation and integration issues during the development phase to minimise human involvement to lower costs.
After developing the assay technology, companies focus on their licensing and commercialisation. Researching universities seek companies that can take a product from being a prototype to the commercialisation phase through manufacturing, testing, clinical trials, regulatory review and approval.
"All assay platforms need a huge amount of validation over many years with a wide range of patient subjects as well as huge investments," observes Mr. Thukral. "Moreover, manufacturing companies need to produce systems that are smaller, faster and easy to use."
The path to commercialisation of a technology also involves meeting regulations, which may differ between various countries. Although the in-vitro diagnostics directive issued by the EU has helped consolidate regulations and requirements for each European country, the governments have to sort out issues related to the number of languages to be used for device labelling.
While the directive countries had printed instructions in their native languages, current regulations require the companies to label their products in 15 languages if it has to be approved for marketing in the EU. Further changes in this directive are expected with additions of new countries to the EU.
As part of regulations, companies may have to file for reimbursements separately in different countries for each assay added to their analyser. However, budgetary pressures have compelled governments to limit the reimbursements provided for assays. As a result, healthcare systems have to choose between better clinical tests at higher prices and those that offer lesser sensitivity and accuracy at lower prices.
Nevertheless, the cost-containment measures of governments could compel healthcare organisations to use reliable, sensitive and preventive assays to improve the quality of healthcare. This can, in turn, help them save considerable amounts of money.
In-Vitro Diagnostics - Industry Impact is part of the Technical Insights-Healthcare vertical subscription service. The study offers an analysis of recent developments in the in-vitro diagnostics industry and identifies commercial applications. This research service enables companies to align their positioning strategies to benefit from emerging technologies. Executive summaries and analyst interviews are available to the press.
If you are interested in an analysis, which provides manufacturers, end users, and other industry participants an overview, summary, challenges, and latest coverage of In-Vitro Diagnostics - Industry Impact, then send an e-mail to Radhika Menon Theodore, Corporate Communications, at rmtheodore@frost.com with your full name, company name, title, telephone number, fax number, and e-mail address. Upon receipt of the above information, an overview will be sent to you by e-mail.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
In-Vitro Diagnostics - Industry Impact D433 Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Trisha Bradley Corporate Communications - Americas P: +1-210-247-3870 F: +1-210-348-1003 E: trisha.Bradley@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-343 E: sdedhia@frost.com Pramila Gurtoo Corporate Communications - Asia Pacific P: (+603)-6204-5811 F: (+603)-6201-7402 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252-8066 E: sjassal@frost.comwww.frost.comwww.technicalinsights.frost.com
Keywords in this release: in-vitro diagnostics, molecular diagnostics, Selectis Bone Quality Test, BQT, peripheral blood, Raman laser system, gene expression pattern, in-vitro diagnostics directive Frost & Sullivan
Frost & SullivanCONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com,Trisha Bradley, Corporate Communications - Americas, P: +1-210-247-3870, F:+1-210-348-1003, E: trisha.Bradley@frost.com, Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com, PramilaGurtoo, Corporate Communications - Asia Pacific, P: (+603)-6204-5811, F:(+603)-6201-7402, E: jkaur@frost.com, Sharmin Jassal, CorporateCommunications - Australia, P: +61-2-8247-8900, F: +61-2-9252-8066, E:sjassal@frost.com
